Effect of amantadine in essential tremor: A randomized, placebo-controlled trial

Movement Disorders

Volumn 21, Issue 4, 2006, Pages 441-445

  Gironell, Alexandre ^a   Kulisevsky, Jaime ^a   Pascual Sedano, Berta ^a   Flamarich, David ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Accelerometry; Amantadine; Essential tremor

Indexed keywords

AMANTADINE; PLACEBO;

ACCELEROMETRY; ADL DISABILITY; ADULT; AGED; ANALYSIS OF VARIANCE; ANXIETY; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESSENTIAL TREMOR; FEMALE; HAND TREMOR; HUMAN; MALE; NERVOUSNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SELF REPORT; SIDE EFFECT; SLEEP DISORDER; STATISTICAL SIGNIFICANCE; TASK PERFORMANCE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; XEROSTOMIA;

AGED; AMANTADINE; ANTIPARKINSON AGENTS; CROSS-OVER STUDIES; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; ESSENTIAL TREMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; NEUROPHYSIOLOGY; TREATMENT OUTCOME;

EID: 33646266490     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20676     Document Type: Article

References (26)

1. Louis ED. Essential tremor. Arch Neurol 2000;57:1522-1524.
2. Gironell A, Kulisevsky J, Barbanoj M, et al. Temblor postural: estudio clínico y neurofisiológico en una serie consecutiva. de 300 pacientes. Med Clin (Barc) 200 1; 117:601-605.
3. Hubble JP, Busenbark KL, Koller WC. Essential tremor. Clin Neuropharmacol 1989;12:453-482.
4. Winkler GF, Young RR. Efficacy of chronic propranolol therapy in action tremors of the familial, senile or essential varieties. N Engl J Med 1974;290:984-988.
5. Chakrabarti A, Pearce JMS. Essential tremor: response to primidone. J Neurol Neurosurg Psychiatry 1981;44:650.
6. Gorman WP, Cooper R, Pocock P, Campbell MJ. A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis. J Neurol Neurosurg Psychiatry 1986;49:64-68.
7. Fleming DM. Managing influenza: amantadine, rimantadine and beyond. Int J Clin Pract 2001;55:189-195.
8. Gualtieri T, Chandler M, Coons TB, Brown LT. Amantadine: a new clinical profile for traumatic brain injury. Clin Neuropharmacol 1989;12:258-270.
9. Kemp BA, Gora ML. Amantadine and fatigue of multiple sclerosis. Ann Pharmacother 1993;27:893-895.
10. Uitti RJ. More recent lessons from amantadine. Neurology 1999; 52:676.
11. Rajput AH, Rajput A, Lang AE, et al. New use for an old drug: amantadine benefits levodopa-induced dyskinesia. Mov Disord 1998; 13:851.
12. Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonsits with neuroprotective properties. J Neural Transm Suppl 1994;43:91-104.
13. Uitti RJ, Raijput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996;46:1551-1556.
14. Kulisevsky J, Tolosa E. Amantadine. In: Pahwa R, Lyons KE, Koller WC, editors. Therapy of Parkinson's disease. New York: Marcel Dekker; 2004. p 233-245.
15. Critchley E. Clinical manifestations of essential tremor. J Neurol Neurosurg Psychiatry 1972;35:365-372.
16. Manyam BV. Amantadine in essential tremor. Ann Neurol 1981, 9:198-199.
17. Koller WC. Amantadine in essential tremor. Ann Neurol 1994;16: 621-622.
18. Obeso JA, Luquin MR, Artieda, J, Martinez-Lage JM. Amantadine may be useful in essential tremor. Ann Neurol 1986;19:99-100.
19. Deuschl G, Bain P, Brin M, et al. Consensus statement of the Movement Disorder Society on tremor. Mov Disord 1998; 13(Suppl. 3):2-23.
20. Gironell A, Kulisevsky J, Pascual-Sedano B, Barbanoj M. Routine neurophysiological tremor analysis as a diagnostic tool for essential tremor: a prospective study. J Clin Neurophysiol 2004;21:446-450.
21. World Medical Assembly. Recommendations guiding physicians in biomedical research involving human subjects. In: XVIII World Medical Assembly, Helsinki, June 1964, and XLI World Medical Assembly, Hong Kong, September 1989.
22. Fahn S, Tolosa E, Marin C. Clinical rating scale for tremor. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore-Munich: Urban and Shwarzenberg; 1988. p 225-234.
23. Gironell A, Kulisevsky J, Barbanoj M, et al. A double-blind placebo-controlled trial of gabapentin and propranolol in patients with essential tremor. Arch Neurol 1999;56:475-480.
24. Bain PG, Findley LJ, Atchinson P, et al. Assessing tremor severity. J Neurol Neurosurg Psychiatry 1993;56:868-873.
25. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channes. Eur J Pharmacol 1989;166:591-592.
26. Deep P, Dagher A, Sadikot A, Gjedde A, Cumming P. Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. Synapse 1999;34:313-318.